Prostate Cancer Clinical Trial
— LIAM McOfficial title:
Linking In With Advice and Supports for Men Impacted by Metastatic Cancer
NCT number | NCT05946993 |
Other study ID # | 22052 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 8, 2023 |
Est. completion date | April 2025 |
To evaluate the feasibility of introducing a men's cancer survivorship programme into routine follow up care in patients with advanced genitourinary malignancies.
Status | Recruiting |
Enrollment | 72 |
Est. completion date | April 2025 |
Est. primary completion date | April 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Men aged = 18 years of age at the time of study enrolment. 2. Willing to participate in a 12-week intervention programme and follow up procedures as outlined in the Schedule of Activities section. 3. ECOG performance status 0-2. 4. Recovery to CTCAE Grade =2 adverse events from all prior therapies, or adequately recovered adverse events whereby, whereby the PI feels they will not impact the participants ability to complete the 12-week intervention. 5. Disease-specific inclusion criteria: Prostate cancer: - Histologically confirmed prostate cancer - Must have commenced Androgen Deprivation Therapy (ADT) in the form of a gonadotropin-releasing hormone (GnRH) analogue or a GnRH receptor antagonist and/or an androgen receptor antagonist and/or undergone bilateral orchidectomy for prostate cancer. Men must have received last ADT treatment within 12 months of starting the programme or have ongoing treatment-related side effects at the time of commencing the programme if ADT has been discontinued due to toxicity. - Patients without histologically confirmed cancer are eligible if both the treating physician and the study PI agree that the patient's history is unambiguously indicative of advanced prostate cancer (e.g. high Prostate-specific antigen (PSA) responsive to ADT in prostate cancer). Urothelial tract cancer: - Stage II - IV urothelial tract cancer (muscle-invasive, node positive or metastatic disease) after completion of primary treatment with systemic therapy (including in the neoadjuvant or adjuvant setting) and/or surgery and recovery from these treatments to a satisfactory level. - Patients with metastatic disease continuing on maintenance systemic therapy are permitted if they do not have ongoing CTCAE Grade >2 adverse events which will impact their participation at the time of commencing the 12-week programme. Kidney cancer: • Stage II - III renal cell cancer (clear cell or non-clear cell histologies permitted) after nephrectomy who required and have commenced or completed adjuvant systemic therapy within the past 12 months and have recovered from these treatments to CTCAE Grade =2 or do not have ongoing CTCAE Grade >2 adverse events at the time of commencing the 12-week programme from ongoing systemic therapy. Or • Stage IV renal cell cancer (clear cell or non-clear cell histologies permitted) where the participants are continuing on stable dose of maintenance systemic therapy and do not have ongoing CTCAE Grade >2 adverse events at the time of commencing the 12-week programme. Testicular cancer: • Stage II-III testicular cancer after completion of primary treatment with systemic therapy and/or surgery within the past 12 months and recovery of all adverse events from these treatments to CTCAE Grade =2. Penile Cancer: - Stage III - IV penile cancer (node positive, recurrent or metastatic disease) after completion of primary treatment with systemic therapy (including in the neoadjuvant or adjuvant setting) and/or surgery and recovery from these treatments to CTCAE Grade =2. - Patients with metastatic disease continuing maintenance systemic therapy are permitted if they do not have ongoing CTCAE Grade >2 adverse events which will impact their participation at the time of commencing the 12-week programme. 6. Participation in other translational or interventional clinical trials is permitted provided the above disease-specific inclusion criteria are met. 7. Signed consent form by the participant or a legally authorized representative (LAR). Exclusion Criteria: 1. Persons who, in the opinion of the researcher or supervising clinician, are unable to cooperate adequately with the study protocol, for example those receiving systemic therapy for a concurrent cancer diagnosis, those with organ system dysfunction which would impact their safe participation in the study, or other uncontrolled medical illness that would impact their safe participation in the study. 2. Recent (within 12 months) participation in a study/programme involving a lifestyle intervention (e.g diet, exercise, survivorship). 1. Note: Per discretion of PI as to whether may impact the outcome of this study intervention. |
Country | Name | City | State |
---|---|---|---|
Ireland | Cork University Hospital | Cork |
Lead Sponsor | Collaborator |
---|---|
University College Cork | Cancer Research@UCC, Irish Cancer Society |
Ireland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility as assessed by a purposefully designed feasibility questionnaire | The feasibility of introducing a men's cancer survivorship programme into routine follow up care in patients with advanced genitourinary cancer. Purposefully designed feasibility questionnaire will be used. All scores will be linearly transformed to a 0 to 100 scale. | At week 12 | |
Primary | Feasibility as assessed by a purposefully designed feasibility questionnaire | The feasibility of introducing a men's cancer survivorship programme into routine follow up care in patients with advanced genitourinary cancer. Purposefully designed feasibility questionnaire will be used. All scores will be linearly transformed to a 0 to 100 scale. | At 6-month post intervention timepoint | |
Primary | The acceptability of introducing a men's cancer survivorship programme into routine follow up care in patients with advanced genitourinary cancer | Purposefully designed feasibility questionnaire will be used. All scores will be linearly transformed to a 0 to 100 scale. | At week 12 | |
Primary | The acceptability of introducing a men's cancer survivorship programme into routine follow up care in patients with advanced genitourinary cancer | Purposefully designed feasibility questionnaire will be used. All scores will be linearly transformed to a 0 to 100 scale. | At the 6-month post intervention timepoint | |
Secondary | Change from Baseline in Health related-Quality of Life Questionnaire (QLQ) scores assessed by European Organization for the Research and Treatment of Cancer (EORTC) | Quality of Life survey; European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QoL).
All patients will answer at the baseline and at the end of the intervention EORTC QLQ-C30 (30 items). The scoring will be performed according to the EORTC scoring manual. All scores will be linearly transformed to a 0 to 100 scale. |
Baseline and at the end of the 12-week programme | |
Secondary | Change from Baseline in Fatigue related-Quality of Life Questionnaire (QLQ) scores | Cancer related fatigue score; European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-FA12).
All patients will answer at the baseline and at the end of the intervention, week 12. All scores will be linearly transformed to a 0 to 100 scale. |
Baseline and at the end of the 12-week programme | |
Secondary | Change from Baseline in weight. | The dietitian will perform physical assessments of each patient at the baseline and at the end of the study. The dietitian will record the weight in kg. | Baseline and the programme endpoint (12 weeks). | |
Secondary | Change from Baseline in muscle strength and mass. | The physiotherapist will perform physical assessments of each patient at the baseline and at the end of the study. The physiotherapist will measure the muscle strength and mass through leg extension and biceps curl in kg. | Baseline and the programme endpoint (12 weeks). | |
Secondary | Change from Baseline in 6-minute walk test. | The physiotherapist will perform 6-minute walk test and measure it in metres (m). | Baseline and the programme endpoint (12 weeks). | |
Secondary | Change from Baseline in muscle strength scores on handgrip measurements | The dietitian will perform physical assessments to each patient at the baseline and at the end of the study. Muscle strength will be measured using hand grip strength (HGS) based on the Jamar Dynamometer (Model 091011725). | Baseline and the programme endpoint (12 weeks). | |
Secondary | Change from Baseline in Diet intake scores from multiple 24-hour recalls, complemented by a Food Frequency Questionnaire (FFQ) | All patients will answer at the baseline and at the end of the intervention the FFQ. All patients will answer at the baseline and at the end of the intervention the Food Frequency Questionnaire. Data will be entered in to the FFQ European Prospective Investigation into Cancer and Nutrition (EPIC) Tool for Analysis (FETA). FETA calculates the average daily intake of 46 nutrients and 14 food groups, for each individual. The default nutrients list provides a description of each nutrient/food group and the units used. The nutrient data for the FFQ foods have come from McCance and Widdowson's "The Composition of Foods (5th edition)" and its associated supplements. | Baseline and the programme endpoint (12 weeks). | |
Secondary | Change from Baseline in Diet quality scores from The World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) standardised scoring system (Shams-White et al 2019). | All patients will answer at the baseline and at the end of the intervention the WCRF/AICR. The higher the score, the better Diet quality. | Baseline and the programme endpoint (12 weeks). | |
Secondary | Change from Baseline in BMI scores. | The dietitian will perform physical assessments of each patient at the baseline and at the end of the study. Weight and height will be combined to report BMI in kg/m^2. Weight will be reported in kg. | Baseline and the programme endpoint (12 weeks). | |
Secondary | Change from Baseline in Lean Body Mass (LBM) scores. | The dietitian will perform physical assessments of each patient at the baseline and at the end of the study. Weight and body fat will be combined to report LBM in kg*(Percentage body/100). | Baseline and the programme endpoint (12 weeks). | |
Secondary | Change from Baseline in waist circumference scores. | The dietitian will perform physical assessments of each patient at the baseline and at the end of the study. Waist circumference will be measured in cm. | Baseline and the programme endpoint (12 weeks). | |
Secondary | Change from Baseline in Segmental Body Composition scores assessed measured by Body Composition Monitor bioimpedance spectroscopy (BIS). | The dietitian will perform physical assessments on each patient at the baseline and at the end of the study. Weight (Kg) and body fat (%) and Total Body Water (TBW) will be combined to report the Body Composition score. | Baseline and the programme endpoint (12 weeks). | |
Secondary | Change from Baseline in Nutritional risk scores assessed by the Malnutrition Screening Tool (MST) | All patients will complete the MST at the baseline and at the end of the intervention. The higher the score, the higher risk of malnutrition. | Baseline and the programme endpoint (12 weeks). | |
Secondary | Self-care agency and its relationship to quality of life and symptoms experienced | Instruments to measure self-care agency include the ASAS-R
Additional Assessments as identified by the scoping review will be included in the Expansion Phase. The higher the score, the better the self-care agency. |
Baseline and the programme endpoint (12 weeks). | |
Secondary | The resource utilisation of signposted services among participants in the 12-week intervention programme | Quality-adjusted life-year (QALY) (EQ-5D-5L). A high score represents high functionality problems. | Baseline and the programme endpoint (12 weeks). A high score represents high functionality problems. | |
Secondary | Satisfaction of participants and Health Care Professionals with the programme and their perceptions of the systems usability. | Qualitative analysis of Usability, Satisfaction and Feasibility Questionnaire Participants, health care professionals and the broader team involved in the development and implementation of the programme will be invited to provide feedback after the completion of their involvement in the study. The higher the score, the better usability and satisfaction from the participant | At the programme endpoint (12 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |